FIELD: pharmacology.
SUBSTANCE: group of inventions represents: an ophthalmic suspension, containing cyclosporine A of form 2 and some medium, where cyclosporine A of form 2 is characterized by peaks in X-ray diffractometer scanning with the radiation of Cu Kα, 2θ: 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5; method of preparation of cyclosporine composition, which includes the stages of mixing cyclosporine A of form 2 with the medium for producing the suspension; suspension quassation; ophthalmic suspension, containing particles of cyclosporine A of form 2; and the medium, in which the average particle size (d90) is less than about 10 micron; method of treatment of a condition selected from: dry eye syndrome, blepharitis, tarsal glands disease, impaired awareness of corneal, allergic conjunctivitis, atopic keratoconjunctivitis, spring keratoconjunctivitis and pterygium, including the stage of applying said ophthalmic suspension to the patient, being in this condition.
EFFECT: increased bioavailability, reduced foreign body sensation and achieved high stability.
15 cl, 18 dwg, 2 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION OF PROLONGED ACTION OF CYCLOSPORIN OF FORM 2 | 2012 |
|
RU2639393C2 |
AUTOCLAVABLE FORM 2 CYCLOSPORIN A PORTION | 2012 |
|
RU2630970C2 |
FORM OF 2 CYCLOSPORIN A AND METHOD OF ITS PRODUCTION | 2012 |
|
RU2635547C2 |
METHOD OF TREATING INFLAMMATIONS OF ANTERIOR EYE SEGMENT | 2013 |
|
RU2513597C1 |
CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS FOR PREPARATION AND METHODS FOR USE THEREOF | 2012 |
|
RU2602062C2 |
OPHTHALMIC COMPOSITION CONTAINING CYCLOSPORINE AND TREHALOSE | 2015 |
|
RU2700927C2 |
ARTIFICIAL TEARS AND THERAPEUTIC APPLICATION | 2010 |
|
RU2589837C2 |
SUSPENSION COMPOSITIONS OF CYCLOSPORINE A FOR SUBCONJUNCTIVAL AND PERIOCULAR INJECTION | 2015 |
|
RU2713953C2 |
METHOD FOR TREATMENT OF HEAVY FORMS OF DRY KERATOCONJUNCTIVITIS | 2016 |
|
RU2621553C1 |
METHOD OF AGENT SCREENING, SUITABLE FOR TREATMENT OF DRY EYE SYNDROME AND/OR INJURY OF CORNEA AND CONJUNCTIVA, PHARMACEUTICAL COMPOSITION, OBTAINED BY THEREOF | 2010 |
|
RU2564912C2 |
Authors
Dates
2018-01-23—Published
2012-11-14—Filed